文献速递产科母胎医学

妊娠期新冠疫苗接种与奥密克戎变异株流行期间新生儿结局:INTERCOVID-2022研究

Maternal vaccination against COVID-19 and neonatal outcomes during Omicron: INTERCOVID-2022 study.
PubMed 文献 · Am J Obstet Gynecol · 2024-02-16

INTERCOVID-2022是一项在18个国家40家医院开展的前瞻性观察性研究,纳入4707名新生儿,比较确诊新冠孕妇与未确诊孕妇的新生儿结局。奥密克戎流行期间,未接种疫苗母亲的新生儿死亡风险为未确诊母亲新生儿的2.06倍,接种加强针母亲的新生儿新冠检测阳性风险仅为未接种者的0.46倍,且早产等不良结局最低。疫苗保护效果随时间下降,建议在预产期前14周内接种疫苗或加强针。

要点

  • 未接种疫苗母亲的新生儿死亡风险是未确诊母亲新生儿的2.06倍(95%CI 1.06-4.00)。
  • 接种加强针母亲的新生儿新冠检测阳性风险为未接种者的0.46倍(95%CI 0.23-0.91),疫苗有效性64%。
  • 建议在预产期前14周内接种疫苗或加强针以最大化新生儿保护。

核心结论

  • 奥密克戎流行期间,未接种疫苗母亲的新生儿死亡风险增加;接种疫苗母亲的新生儿早产和不良新生儿结局风险降低。
  • 新冠疫苗保护效果随时间下降,为确保新生儿获得最大保护,母亲应在预产期前不超过14周接种疫苗或加强针。

研究设计与样本

  • INTERCOVID-2022为大型前瞻性观察性研究,于2021年11月27日至2022年6月30日在18个国家40家医院开展。
  • 纳入确诊新冠孕妇所生新生儿1577名(33.5%)和未确诊孕妇所生新生儿3130名(66.5%),共4707名新生儿,随访至出院。
  • 确诊孕妇中,642名(40.7%)未接种疫苗,147名(9.3%)部分接种,551名(34.9%)完全接种,237名(15.0%)接种加强针。

主要发现

  • 与未接种疫苗母亲的新生儿相比,接种加强针母亲的新生儿新冠检测阳性风险降低(相对风险0.46,95%CI 0.23-0.91),且早产、医学指征早产、呼吸窘迫综合征发生率及新生儿重症监护病房住院天数最低。
  • 未接种疫苗母亲的新生儿死亡风险是未确诊母亲新生儿的2.06倍(95%CI 1.06-4.00)。
  • 接种加强针母亲的新生儿疫苗有效性最高(64%,95%CI 10%-86%),所有疫苗均提供保护;仅信使RNA疫苗时,完全接种和加强接种组对中重度新生儿结局的疫苗有效性分别为25%和28%,加强接种组(所有疫苗)为13%。
  • 母亲在分娩前≤100天(14周)接种疫苗对新生儿保护较好,之后风险增加,超过200天(29周)后风险更高。
  • 所研究的新生儿实践(包括皮肤接触和直接母乳喂养)均未增加新生儿感染风险,且接种疫苗与任何先天畸形无关。

临床怎么用

  • 作者建议,为确保新生儿获得最大保护,母亲应在预产期前不超过14周接种疫苗或加强针。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In early 2023, when Omicron was the variant of concern, we showed that vaccinating pregnant women decreased the risk for severe COVID-19-related complications and maternal morbidity and mortality. OBJECTIVE: This study aimed to analyze the impact of COVID-19 during pregnancy on newborns and the effects of maternal COVID-19 vaccination on neonatal outcomes when Omicron was the variant of concern. STUDY DESIGN: INTERCOVID-2022 was a large, prospective, observational study, conducted in 40 hospitals across 18 countries, from November 27, 2021 (the day after the World Health Organization declared Omicron the variant of concern) to June 30, 2022, to assess the effect of COVID-19 in pregnancy on maternal and neonatal outcomes and to assess vaccine effectiveness. Women diagnosed with laboratory-confirmed COVID-19 during pregnancy were compared with 2 nondiagnosed, unmatched women recruited concomitantly and consecutively during pregnancy or at delivery. Mother-newborn dyads were followed until hospital discharge. The primary outcomes were a neonatal positive test for COVID-19, severe neonatal morbidity index, severe perinatal morbidity and mortality index, preterm birth, neonatal death, referral to neonatal intensive care unit, and diseases during the neonatal period. Vaccine effectiveness was estimated with adjustment for maternal risk profile. RESULTS: We enrolled 4707 neonates born to 1577 (33.5%) mothers diagnosed with COVID-19 and 3130 (66.5%) nondiagnosed mothers. Among the diagnosed mothers, 642 (40.7%) were not vaccinated, 147 (9.3%) were partially vaccinated, 551 (34.9%) were completely vaccinated, and 237 (15.0%) also had a booster vaccine. Neonates of booster-vaccinated mothers had less than half (relative risk, 0.46; 95% confidence interval, 0.23-0.91) the risk of being diagnosed with COVID-19 when compared with those of unvaccinated mothers; they also had the lowest rates of preterm birth, medically indicated preterm birth, respiratory distress syndrome, and number of days in the neonatal intensive care unit. Newborns of unvaccinated mothers had double the risk for neonatal death (relative risk, 2.06; 95% confidence interval, 1.06-4.00) when compared with those of nondiagnosed mothers. Vaccination was not associated with any congenital malformations. Although all vaccines provided protection against neonatal test positivity, newborns of booster-vaccinated mothers had the highest vaccine effectiveness (64%; 95% confidence interval, 10%-86%). Vaccine effectiveness was not as high for messenger RNA vaccines only. Vaccine effectiveness against moderate or severe neonatal outcomes was much lower, namely 13% in the booster-vaccinated group (all vaccines) and 25% and 28% in the completely and booster-vaccinated groups, respectively (messenger RNA vaccines only). Vaccines were fairly effective in protecting neonates when given to pregnant women ≤100 days (14 weeks) before birth; thereafter, the risk increased and was much higher after 200 days (29 weeks). Finally, none of the neonatal practices studied, including skin-to-skin contact and direct breastfeeding, increased the risk for infecting newborns. CONCLUSION: When Omicron was the variant of concern, newborns of unvaccinated mothers had an increased risk for neonatal death. Neonates of vaccinated mothers had a decreased risk for preterm birth and adverse neonatal outcomes. Because the protective effect of COVID-19 vaccination decreases with time, to ensure that newborns are maximally protected against COVID-19, mothers should receive a vaccine or booster dose no more than 14 weeks before the expected date of delivery.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Barros FC, Gunier RB, Rego A, et al. Maternal vaccination against COVID-19 and neonatal outcomes during Omicron: INTERCOVID-2022 study. Am J Obstet Gynecol. 2024. PMID: 38367758. doi:10.1016/j.ajog.2024.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。